Intermediate maple syrup urine disease

Intermediate maple syrup urine disease (intermediate MSUD) is a rare inherited metabolic disorder and one of the milder variant forms of maple syrup urine disease. It is caused by a partial deficiency of the branched-chain alpha-ketoacid dehydrogenase (BCKD) enzyme complex, which is responsible for breaking down the branched-chain amino acids (BCAAs) leucine, isoleucine, and valine. Because this enzyme retains some residual activity (typically 3–30% of normal), the clinical presentation is less severe than the classic form of MSUD. The condition is characterized by chronically elevated levels of BCAAs and their corresponding ketoacids in the blood and urine, which gives urine a characteristic sweet, maple syrup-like odor. Intermediate MSUD primarily affects the nervous system. Patients may present with developmental delay, intellectual disability, feeding difficulties, and failure to thrive during infancy or childhood, though some individuals may not be diagnosed until later in life. Unlike classic MSUD, patients with the intermediate form typically do not experience the severe neonatal metabolic crisis seen in the first days of life. However, during periods of physiological stress such as illness, surgery, or fasting, patients can develop acute metabolic decompensation with encephalopathy, ataxia, seizures, and potentially life-threatening neurological complications. The characteristic maple syrup odor of urine and cerumen may be present intermittently or persistently. Treatment of intermediate MSUD centers on dietary management with restriction of branched-chain amino acid intake to maintain plasma leucine levels within a safe therapeutic range. A specialized medical formula that provides protein without excessive BCAAs is typically used. Regular monitoring of plasma amino acid levels is essential. During acute illness or metabolic stress, emergency protocols including increased caloric intake and sometimes intravenous glucose are necessary to prevent catabolism and metabolic crisis. Thiamine supplementation may be trialed, as some patients with intermediate MSUD are thiamine-responsive. Liver transplantation has been performed in some cases of MSUD and can be curative by providing sufficient enzyme activity, though it is generally reserved for more severe or difficult-to-manage cases. Newborn screening programs using tandem mass spectrometry can detect elevated BCAAs, enabling early diagnosis and intervention.

Common questions about Intermediate maple syrup urine disease